Here are five points:
1. The shares bought are valued at approximately $2.06 million.
2. The company currently has an average rating of “buy” and an average target price of $58.54 from all brokerages covering the firm.
3. NuVasive stock has a 50-day moving average price of $46.90 and a 200-day moving average price of $48.38.
4. NuVasive has a 52-week low of $36.81 and a 52-week high of $56.61.
5. The company’s stock has a market capitalization of $2.53 billion.
More articles on devices:
47 spine, orthopedic devices receive FDA 510(k) clearance in March
Kenai Spine debuts exoskeleton bionic robot — 5 highlights
Amedica shares gain 23.93% following Weigao Orthopedic partnership agreement: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
